Gujarat Themis Biosyn Launches QIP Process

Floor Price: Rs 372.57 per equity share
Discount: Up to 5% on the floor price

Reader Takeaway: The QIP signals planned capital expansion; monitor institutional subscription interest and potential EPS dilution impacts.

What just happened

Gujarat Themis Biosyn Limited has officially commenced its Qualified Institutions Placement (QIP) to raise capital. This follows the board of directors' approval on August 25, 2026, aligned with shareholder authorizations granted on August 22, 2026. The company has adopted the preliminary placement document and is now inviting bids from eligible Qualified Institutional Buyers (QIBs).

Pricing Terms

The company set August 25, 2026, as the 'Relevant Date' for the issuance. Under the SEBI (ICDR) regulations, the floor price has been fixed at Rs 372.57 per share. The company retains the board's discretion to offer a discount of up to 5% on this floor price for the final allocation, which will be determined following the bidding process.

Trading Window Compliance

In accordance with its internal Code of Conduct, Gujarat Themis Biosyn has imposed a closure on the trading window for all designated persons. This restriction became effective on August 25, 2026, and will remain in effect until 48 hours after the final issue price is formally determined and communicated to the exchanges.

What to track next

Investors should closely watch for the announcement of the final issue price and the total amount raised. High institutional demand often signals market confidence, but shareholders should assess the level of equity dilution resulting from this fresh issue and its subsequent impact on future earnings per share.